ION expands ETF trading capabilities with Tradeweb integration
Director Maggie Yuen of AtriCure, Inc. (NASDAQ:ATRC) sold 3,000 shares of common stock on November 21, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at prices ranging from $35.71 to $35.76, with an average price of $35.72, totaling $107,160. The stock has since climbed to $37.74, representing a significant 13.8% return over the past week. InvestingPro analysis indicates the stock is trading slightly above its Fair Value.
Following the transaction, Yuen directly owns 11,371 shares of AtriCure . The medical device company, with a market capitalization of $1.88 billion, operates with a moderate debt level and maintains strong liquidity with current assets exceeding short-term obligations by nearly 4x. Despite not being profitable over the last twelve months, AtriCure enjoys a bullish analyst consensus. Discover more insights with InvestingPro, offering comprehensive Pro Research Reports on over 1,400 US equities including ATRC.
In other recent news, AtriCure reported its third-quarter 2025 financial results, showcasing a revenue of $134.3 million. This figure represents a 15.1% year-over-year growth on a constant currency basis and surpassed both Canaccord Genuity’s estimate of $131.6 million and the consensus forecast of $131.3 million. The company’s earnings per share (EPS) also beat expectations, coming in at -$0.01 compared to the forecasted -$0.11. Following these strong results, Canaccord Genuity raised its price target for AtriCure to $64 while maintaining a Buy rating. Needham also maintained its Buy rating and $45 price target, citing better-than-expected revenue, EBITDA, and earnings per share. AtriCure’s management responded to the strong performance by raising its full-year 2025 guidance across all key metrics. Citizens reiterated its Market Outperform rating with a $60 price target after AtriCure’s adjusted EBITDA more than doubled to $17.8 million, surpassing Street expectations. Despite these positive developments, the stock experienced a decline in after-hours trading.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.